Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers

NCT07801313 | Completed Phase 1

• 1 other identifier: MWN105-I
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of MWN105 injection in healthy Chinese volunteers, and to provide a reference for the next clinical trial. This study includes a single ascending dose (SAD) study and a multiple ascending dose (MAD) study. The SAD study consists of 4 dose groups; the MAD study consists of 2 dose groups and adopts a 4-week dose titration scheme. The study plans to enroll 55 volunteers. The primary endpoint is the incidence of adverse events. The secondary endpoints are the pharmacokinetic and pharmacodynamic characteristics and immunogenicity endpoints.

Conditions

Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM); MASH - Metabolic Dysfunction-Associated Steatohepatitis

Outcome Measures

Primary Outcomes (1)

• Incidence of adverse events (AEs)

  The incidence of adverse events (AEs) and serious adverse events (SAEs).

  From Day 1 to Day 50

Secondary Outcomes (18)

• Maximum Concentration (Cmax)

  From Day 1 to Day 29

• Time to Reach Maximum Concentration (Tmax)

  From Day 1 to Day 29

• Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

  From Day 1 to Day 29

• Area Under the Curve From Time 0 to Infinity (AUC0-inf)

  From Day 1 to Day 29

• Elimination Half-Life (t1/2)

  From Day 1 to Day 29

Study Arms (2)

MWN105 S

EXPERIMENTAL

MWN105 S consists of 4 dose groups, with doses ranging from 3 mg to 30 mg. Healthy participants in all dose groups were randomly assigned to receive a single subcutaneous dose of MWN105 or placebo.

Drug: MWN105; Drug: Placebo

MWN105 M

EXPERIMENTAL

MWN105 Cohort M consists of 2 dose groups. In all dose groups, Healthy participants are randomized to receive 4 subcutaneous doses of MWN105 or placebo, administered once weekly.

Drug: MWN105; Drug: Placebo

Interventions

MWN105 DRUG

S1, S2 S3, S4; administered subcutaneously (SC)

MWN105 S

Placebo DRUG

administered SC

MWN105 M; MWN105 S

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The selected subjects should be healthy male or female individuals aged 18 to 45 years (inclusive).
• Female subjects should have a body weight of at least 50.0 kg, and male subjects should have a body weight of at least 55.0 kg. Their body mass index (BMI) should be within the range of 19.0-28.0 kg/m² (inclusive).
• Physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasound, and clinical laboratory test results (including serum calcitonin, coagulation function, and thyroid function) should show no clinically significant abnormalities.
• Subjects are required to abstain from sexual activity or use two effective contraceptive methods simultaneously starting from 1 month before screening through 6 months after the last administration, and must have no plans for sperm or egg donation.

You may not qualify if:

• Any history of clinical severe diseases or current presence of any clinically significant diseases.
• Those with a known history or family history of medullary thyroid carcinoma, type 2 multiple endocrine neoplasia syndrome (MEN2), or those with a history of hypothyroidism or abnormal thyroid hormone levels.
• Subjects with a history of acute or chronic pancreatitis, symptomatic gallbladder disease, history of pancreatic injury, or other high-risk factors that may cause pancreatitis, or those with an amylase level \> 1.5 times the upper limit of the normal range (ULN) during screening.
• Those with clinically significant gastric emptying abnormalities (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as having had active ulcers within 6 months), long-term use of drugs that directly affect gastrointestinal motility (including but not limited to mosapride, cispamide), or those who have undergone gastrointestinal surgery within 12 weeks before screening and are assessed by the investigator as not suitable to participate in this clinical study.
• Used any prescription drugs, herbal medicines, over-the-counter drugs, or dietary supplements within 2 weeks before administration.
• Had an infectious disease within 4 weeks before screening, severe trauma, or a history of major surgery.
• Received vaccines or planned to receive vaccines during the trial screening.
• Donated blood, experienced significant blood loss (\> 450 mL), or received a blood transfusion within 12 weeks before screening.

Sponsors & Collaborators

• Shanghai Minwei Biotechnology Co., Ltd: lead

Study Sites (1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Overweight; Obesity; Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2026
• First Posted: September 3, 2026
• Study Start: December 19, 2024
• Primary Completion: July 20, 2025
• Study Completion: July 20, 2025
• Last Updated: September 3, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)